Oxprenolol-non-selective beta blocker with some intrinsic sympathomimetic activity.

Oxprenolol is a non-selective beta blocker with some intrinsic sympathomimetic activity. It is used for the treatment of angina pectoris, abnormal heart rhythms and high blood pressure.

Oxprenolol-non-selective beta blocker with some intrinsic sympathomimetic activity.

Coretal; Dl-Oxprenolol; Trasicor; Oxprenololum

Trasicor

1-[2-(prop-2-en-1-yloxy)phenoxy]-3-[(propan-2-yl)amino]propan-2-ol

Oxprenolol is a non-selective beta blocker with some intrinsic sympathomimetic activity, is a lipophilic beta blocker which passes the BBB (blood-brain barrier) easily than water soluble beta blockers. As such, it is associated with a higher incidence of CNS-related side effects than hydrophilic ligands such as atenolol, sotalol and nadolol.

The recommended dose is 80-160 mg/day in 2-3 divided doses.

Used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.

CHF, heart block, severe bradycardia, bronchospasm, pulmonary oedema, postural hypotension, prolonged PR interval, sinus arrest, palpitation, chest pain, peripheral vascular disorders, hot flashes, syncope; vertigo, lightheadedness, headache, dizziness, nervousness, anxiety, irritability, depression, sleep disturbances, hallucinations, slurred speech; sedation, dry skin, rash, pruritus; impotence, decreased libido, wt gain, hypoglycaemia; GI disturbances; thrombocytopenia, leukopenia; elevated LFTs; paraesthesia, weakness; keratoconjunctivitis, dry and itching eyes, blurred vision; tinnitus; increased BUN; dyspnoea, wheezing; diaphoresis.

• Hypotension, cardiac arrhythmias and cardiac arrest may occur with IV diltiazem and verapamil.
• Bradycardic and hypotensive effects may be enhanced by fentanyl.
• Excessive reduction of sympathetic activity may occur with MAOIs, reserpine, guanethidine.
• Effect may be enhanced by cimetidine.
• Additive CNS depression may occur with opiate analgesics, antihistamines, ethanol, psychoactive drugs.
• May enhance the vasoconstrictive effects of ergot alkaloids.
• Effect may be reduced with indometacin (and possibly other NSAIDs).
• May enhance effects of insulin and oral antidiabetics.
• Hypertensive reactions may occur with sympathomimetics e.g. epinephrine.
• Myocardial depression may be additive with inhalant anaesthetics.
• Ephedra, yohimbe and ginseng may exacerbate hypertension.
• May enhance negative inotropic and negative dromotropic effect of quinidine, amiodarone, disopyramide.

Bronchospasm or asthma; sinus bradycardia; 2nd and 3rd degree AV block; uncontrolled heart failure; sick sinus syndrome; right ventricular failure, allergic rhinitis, secondary to pulmonary hypertension; cardiogenic shock.

Store at 30°C (86°F).

Molecular weight

265.348

Molecular formula

C15H23NO3

CAS number

6452-71-7

Precautions

• Oxprenolol is a potent beta-blocker and should not be administered to asthmatics because it can cause irreversible airway failure and inflammation.
• History of severe anaphylaxis to allergens; treatment of anaphylaxis (e.g. epinephrine) may be ineffective in patients on β-blockers.
• Do not withdraw abruptly (particularly in patients with coronary artery disease).
• Compensated heart failure, DM, severe hepatic impairment or inflammatory diseases, myasthenia gravis, peripheral vascular disease (including Raynaud's), untreated phaeochromocytoma, history of psychiatric illness.
• Pregnancy and lactation.
• May impair ability to drive or operate machinery.